Compare L3Harris Technologies Inc (LHX) vs Revvity Inc (RVTY) Price & Performance

LHX trades at $236.97, up 1.43% today, with a bearish technical signal despite strong fundamentals. The company reported revenue of $21.87B in 2025, with net income of $1.61B and improving profit margins. Recent contract wins, including a $6B THAAD propulsion deal with Lockheed Martin, highlight growth prospects. However, multiple law firm investigations into the company have emerged in September 2026, creating investor uncertainty.

The outlook is mixed: analyst consensus is bullish with a $340 price target, but technical indicators and legal overhangs pose risks. Earnings beats in recent quarters support fundamental strength, yet sentiment is tempered by bearish momentum and potential legal liabilities. Upside depends on contract execution and resolution of investigations.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.